Wave Life Sciences, Inc.
Wave Life Sciences, Inc. is a clinical-stage biotechnology company developing RNA medicines for genetic and metabolic diseases. Its platform includes stereopure oligonucleotide design, RNA editing, RNA interference, and other nucleic-acid approaches, with research and development activities conducted through operations in the United States, Japan, Ireland, and the United Kingdom.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaGalNAc-delivered candidates designed to correct or alter disease-associated RNA in liver disorders.
siRNA programs designed to silence disease-related genes, including the INHBE obesity program.
Oligonucleotide therapies intended to modify RNA processing in genetic diseases such as DMD.
PRISM-enabled research programs and partnered oligonucleotide discovery activities.
Asiakkaat
Wave has not generated product revenue and currently derives revenue from collaboration agreements rather than sales to patients or healthcare providers. Its commercial counterparties are biopharmaceutical companies seeking RNA drug discovery, development, licensing, and commercialization capabilities, including GSK and previously Takeda. Future customers could include healthcare systems, physicians, payors, and patients if Wave's clinical candidates receive regulatory approval.
Large drug companies partner with Wave to access RNA biology, PRISM, and development expertise.
Potential partners may license late-stage or approved candidates for global regulatory and commercial execution.
Future providers and insurers could purchase or reimburse approved medicines for eligible patients.
Patients are the intended end users of treatments for obesity, AATD, liver disease, DMD, and other conditions.
Strategia
Wave's strategy is to advance a focused pipeline of RNA medicines while using its PRISM platform and delivery technologies to expand the addressable range of genetic and metabolic diseases. Near-term development centers on WVE-007 for obesity and RNA-editing candidates WVE-006 and WVE-008, while partnerships such as the GSK collaboration provide external validation, potential funding, and commercialization access. The model remains dependent on clinical execution, regulatory progress, and the ability to convert research programs into licensing or product opportunities.
Obesity is a large market where durable dosing and muscle preservation could differentiate the program.
RNA editing may enable durable treatment approaches for genetically defined liver diseases.
Collaborations can provide capital, genetic insights, and commercial capabilities beyond Wave's internal resources.
Multiple modalities and disease areas reduce dependence on any single clinical candidate.
Maantiede
Wave's principal U.S. operations are based in Cambridge, Massachusetts, while subsidiaries and registered offices are located in Japan, Ireland, and the United Kingdom. Research, clinical development, manufacturing coordination, regulatory activity, and collaboration management therefore span North America, Europe, and Asia. The company does not disclose country-level product revenue, and reported revenue has come from collaboration agreements rather than geographic product sales.
Riskit
Wave's value depends on advancing clinical-stage candidates through trials and regulatory review, with no product revenue to offset research and development spending. Clinical failures, safety findings, manufacturing or enrollment problems, and competition from other RNA and obesity therapies could reduce the value of its pipeline. Collaboration concentration, future capital needs, intellectual-property disputes, and cyber incidents affecting Wave or its external providers add financial and operational exposure.
- Clinical and regulatory failureVaikutus: KriittinenTodennäköisyys: Korkea
Candidate medicines must demonstrate safety and efficacy in trials and satisfy regulators before generating product revenue.
Kohdistuu - Funding and continuing lossesVaikutus: KriittinenTodennäköisyys: Korkea
Wave has recurring operating losses and no product revenue, so development depends on capital markets and collaboration proceeds.
Kohdistuu - Clinical supply and outsourcing dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
CROs and CMOs perform important research, trial, and manufacturing activities that may be delayed or disrupted.
Kohdistuu - Competitive technology and market adoptionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Competing RNA, gene therapy, obesity, and conventional medicines may limit differentiation or reduce commercial uptake.
Kohdistuu: Obesity and rare genetic disease markets
- Collaboration concentrationVaikutus: KorkeaTodennäköisyys: Matala
Collaboration revenue and future milestone potential depend materially on partners' continued investment and performance.
Kohdistuu: GSK collaboration and other strategic partnerships
- Cybersecurity and data privacyVaikutus: KorkeaTodennäköisyys: Matala
Breaches could compromise patient health information, intellectual property, research data, and business systems.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätRevenue is earned under collaboration agreements and depends on identifying obligations, allocating consideration, and measuring progress.
Vaikutus: Changes in estimates can shift revenue between reporting periods and materially affect reported results.
Potential development, regulatory, and commercialization milestones require judgments about transaction price and recognition constraints.
Vaikutus: Milestone recognition can create significant revenue volatility when contractual conditions are met.
Research expense includes estimates for external clinical, preclinical, and manufacturing work performed but not yet invoiced.
Vaikutus: Revisions to estimated activity or costs can change research and development expense.
Tax credits are recognized when compliance and receipt are reasonably assured.
Vaikutus: Timing of recognition affects other income and reported net loss.
Facilities and other operating leases create recognized lease commitments across the group's jurisdictions.
Vaikutus: Lease classification and expense recognition affect liabilities, operating expenses, and cash-flow presentation.
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
BioAge Labs, Inc.
BIOA · Pharmaceutical Preparations
Beam Therapeutics Inc.
BEAM · Biological Products, (No Diagnostic Substances)
Maze Therapeutics, Inc.
MAZE · Biological Products, (No Diagnostic Substances)
Benitec Biopharma Inc.
BNTC · Pharmaceutical Preparations
SELLAS Life Sciences Group, Inc.
SLS · Pharmaceutical Preparations
SELLAS Life Sciences Group is a U.S.-based late-stage clinical biopharmaceutical company focused on developing cancer therapeutics.
Silence Therapeutics plc
SLN · Pharmaceutical Preparations
Silence Therapeutics plc is a biotechnology company focused on discovering and developing siRNA-based medicines that silence disease-associated genes through RNA interference.
Päivitetty: 24.9.2026